Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells
NCT ID: NCT02510469
Last Updated: 2017-10-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
48 participants
INTERVENTIONAL
2015-07-31
2018-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Apatinib Maintenance Therapy After Adjuvant Chemotherapy
Apatinib Mesylate Tablets 500 mg qd p.o. after XELOX Adjuvant Chemotherapy (Capectabine 1000mg/m2 po bid d1-14, oxaliplatin 130mg/m2 iv d1, q21d)
Apatinib
Apatinib Mesylate Tablets 500 mg qd p.o.
Only Adjuvant Chemotherapy
No Intervention After XELOX Adjuvant Chemotherapy (Capectabine 1000mg/m2 po bid d1-14, oxaliplatin 130mg/m2 iv d1, q21d)
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Apatinib
Apatinib Mesylate Tablets 500 mg qd p.o.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. ECOG PS of 0-1;
3. Histologically proven gastric cancer of stageⅡA, ⅡB, ⅢA, ⅢB and ⅢC (except level 3 or 4 lymph node high suspicious on imaging or confirm by biopsy. A minimun of 15 examined lymph nodes is recommended). All pts were received D2 gastrectomy;
4. The exfoliative cancer cells detection in peritoneal washes was positive;
5. Complete 8 cycles XELOX adjuvant chemotherapy and no recurrence / metastasis occurred. No more than 28 days from screening time to the end of chemotherapy; XELOX: Capectabine 1000mg/m2 po bid d1-14, oxaliplatin 130mg/m2 iv d1, q21d;
6. Pts never received VEGFR inhibitor treatment(i.e. sorafenib, sunitinib);
7. Major organ function has to meet the following criteria:
ANC ≥ 1.5 × 109 / L HB ≥ 90g / L PLT ≥ 100 × 109 / L Bilirubin \<1.5 times the upper limit of normal (ULN) ALT and AST \<2.5 × ULN
8. An expected survival of ≥ 3 months;
9. Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative. They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men, (previous surgical sterilization accepted), shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug.
10. Patient has to voluntarily join the study and sign the Informed Consent Form for the study;
Exclusion Criteria
2. Subjects with poor-controlled arterial hypertension (systolic blood pressure\> 140 mmHg and diastolic blood pressure \> 90 mm Hg) despite standard medical management; Coronary heart disease greater than ClassII; II-level arrhythmia (including QT interval prolongation, for man ≥ 450 ms, for woman ≥ 470 ms) together with Class II cardiac dysfunction;
3. Subjects with high gastrointestinal bleeding risk, including the following conditions: local active ulcer lesions with positive fecal occult blood test (++); history of black stool, or vomiting blood in the past 2 months;
4. Abnormal Coagulation (INR\>1.5、APTT\>1.5 UNL), with tendency of bleed;
5. Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);
6. Associated with Peritoneal, liver, CNS (central nervous system) or distant metastases;
7. Pregnant or lactating women;
8. Pts with other malignant tumor within 5 years(except cured skin basal cell carcinoma and cervical carcinoma);
9. With psychotropic drug abuse history and can't get rid of or mental disorder patients;
10. Participated in other clinical trials within 4 weeks.
11. Pts received VEGFR inhibitor treatment(i.e. sorafenib, sunitinib);
12. Any other condition that might place the patient at undue risk or preclude a patient from completing the study;
13. Other conditions regimented at investigators' discretion.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jiangsu HengRui Medicine Co., Ltd.
INDUSTRY
Hebei Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Qun Zhao
Principal Investgator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fourth Affiliated Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Ahead-G315
Identifier Type: -
Identifier Source: org_study_id